Vertex Pharmaceuticals shares fell 2.36% on the most recent trading day, closing at $438.92. This drop came even as major indices extended gains, with investors weighing concerns over the company’s upcoming clinical data readouts and potential competition in its cystic fibrosis franchise. Trading volume exceeded the 30-day average by approximately 20%, signaling increased investor activity around the decline.